A b s t r a c t
Diagnostic test accuracy (DTA) studies on fine-needle aspiration cytology (FNAC) often
Fine-needle aspiration cytology (FNAC) is a wellestablished method to diagnose many types of lesions. Overall, it is fast, safe, well-tolerated, and minimally invasive. As with all diagnostic procedures, reliable estimates of diagnostic accuracy are important to obtain because they facilitate comparisons with other diagnostic techniques. Such estimates can be used to determine the value of diagnostic evidence obtained from FNAC relative to evidence obtained from other diagnostic methods such as clinical examination, imaging, and biopsy. Thus, diagnostic test accuracy (DTA) studies are necessary for designing and improving diagnostic algorithms. Finally, estimates from diagnostic accuracy studies are the means by which improvements in FNAC methods are evaluated and used to study causes of performance variation between centers.
There has been increasing awareness of the unique methodological issues associated with DTA; studies and numerous deficiencies have been identified in study design and reporting. [1] [2] [3] [4] [5] These findings have led to efforts such as the STARD initiative, 6, 7 the QUADAS instrument, 8, 9 the QAREL 10 instrument, and the recent initiative by the Cochrane Collaboration to improve the quality of reviews of DTA studies. Diagnostic accuracy studies are frequently published in cytopathology literature. An average of 74 FNAC DTA studies have been published each year for the past decade, and the publication rate has increased in recent years ❚Figure 1❚. Reviews of FNAC have found significant variation in diagnostic performance between studies; however, methodological issues underlying performance variation are poorly understood. 11 Upon completion of this activity you will be able to:
• discuss why complete reporting of methods is important in diagnostic accuracy studies.
• describe current practice in reporting of fine-needle aspiration cytology diagnostic test accuracy studies.
• describe the use of logistic regression analysis.
• name the appropriate statistic for measurement of agreement.
The ASCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ASCP designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit ™ per article. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module.
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FNAC is a complex, multistep process, and each step can be performed in multiple ways. These steps can be broadly categorized as sample collection, sample preparation, and sample interpretation. Differences in each of these steps can lead to differences in test performance. Thus, it is vital for test conditions to be fully described to facilitate valid comparisons between studies. Despite its importance, no studies have been done to evaluate the reporting of test parameters for FNAC DTA studies. We therefore conducted a study to investigate the manner in which test parameters are specified in FNAC DTA studies. In particular, we studied the parameters that are commonly reported, the frequency with which they are reported, the variability in reporting, and whether reporting practice has changed over time.
Materials and Methods

Search
Potential studies were identified by a MEDLINE search using the search terms 
Study Eligibility
One of us (R.L.S.) screened the studies for eligibility. Studies were eligible for inclusion if they contained more than 10 cases with numeric data on DTA (sensitivity and specificity) for FNAC. Studies were not limited by anatomic site or journal specialty.
Survey Item Generation
A list of test parameters was developed by reading the methods sections of 30 FNAC DTA studies and identifying the test parameters (eg, needle size and type of stain) specified in each study. The list of FNAC specifications was then refined through discussion with staff cytologists and pilot tested on an additional 20 studies.
Survey Item Validation
We validated the items on our list by conducting a poll of 7 experienced cytopathologists in which we asked them to rate the importance of each survey item on a scale of 1 to 10 (1 = lowest and 10 = highest; no forced ranking).
Study Evaluation
We created a checklist of the test parameters that we previously identified. The checklist was used to determine which specifications were actually reported in the methods section of each study. Each study was randomly assigned to a team composed of 3 members. Each study was independently evaluated by 3 evaluators. For each study, the evaluator read the methods section and determined whether each survey item was specified.
Experimental Design
A set of eligible studies was identified for each period using the procedure previously described. We randomly selected 33 studies (using a random number generator) from the set of eligible studies from each period. Overall, 99 studies were selected for evaluation. Each of 3 teams was randomly assigned 7 evaluators; 11 studies from each period were randomly selected and assigned to each team. Thus, each team evaluated 33 studies (11 from each period). Studies were evaluated in random order determined by a random number generator. The selection, assignment, and evaluation process is shown in ❚Figure 2❚.
Statistical Analysis
Survey data were recorded in a database (Microsoft Access 2010, Microsoft, Redmond, WA), and all statistical analysis was conducted using STATA Statistical Software, Release 11 (StataCorp, College Station, TX). Agreement was measured by using percentage of agreement and the Cohen κ. Results were considered statistically significant if the P value was less than .05. Multivariate logistic regression was used to assess the effect of various parameters (period, journal type, and test parameter) on the specification rate. The specification rate is defined as the probability that a particular item was specified in the methods section of studies.
Multiple logistic regression analysis is a technique that determines the relationship between various predictors on a binary outcome variable. In this case, the outcome variable is whether a particular test parameter is specified, which we term the specification rate. The model determines the relationship between various predictors (eg, period, journal type, and test parameter) and the probability that a particular test parameter is specified. Multiple logistic regression enables one to determine the effect of one variable after adjusting for the effect of other variables.
The statistical model was as follows:
logit(p ijk ) = β 0 + β Pi P i + β Jj J j + β Tk T k Where p = the specification rate P i = period i, for i = 1, 2, 3 J j = journal type j, for j = 1 (pathology), 2 (cytology), 3 (surgery), and 4 (other) T k = test parameter k, for k = parameters 1 to 17
We also looked at the specification rate by item groups.
Where T m = test parameter type m for m = 1 to 3: 1 = sample collection, 2 = sample preparation, and 3 = sample interpretation
Results
Search for Studies
We identified 156 studies from period 1 (1989-1991 
Characteristics of Selected Studies
The studies were conducted on a wide range of tissues ❚Table 1❚. The most frequent sites were thyroid (20%), breast (16%), lymph nodes (9%), and salivary glands (12%). The studies were published in a range of journals, which we classified into 4 categories: pathology, cytology, surgery, ❚Figure 2❚ Study selection and assignment. A search was conducted to identify fine-needle aspiration cytology accuracy studies from each period. The studies were screened for eligibility, and 33 studies were randomly selected from the set of eligible studies for each period. Each team was randomly assigned 11 studies from each period. (Each team received 33 studies, 11 from each period). The order of evaluation of the 33 articles was randomized. There were 3 teams, each with 7 randomly assigned evaluators. Each study was independently evaluated 3 times. and general medicine. In our sample, studies most frequently appeared in cytology journals (38%) and appeared least frequently in pathology journals (7%). The distribution of studies by journal type is given in ❚Table 2❚.
Survey Item Generation
We identified 17 test parameters that were specified in our initial set of 30 FNAC DTA studies. These items are listed in ❚Table 3❚. We classified the test parameters into 3 categories: sample collection, sample preparation, and sample interpretation.
Survey Item Validation
We conducted a survey of experienced cytopathologists to validate the items on our list of test parameters. Each item was rated on a scale of 1 to 10 (1 = lowest and 10 = highest). The average scores ranged from 3.5 (number of persons performing biopsies) to 9 (cytologist available for immediate assessment). A summary of the cytopathologist survey is presented in ❚Table 4❚.
Specification Rate by Study
The number of items specified per study ranged from 0 to 13 of the 17 items (median, 5; mean, 5; SD, 2.7). The specification by study is presented in ❚Figure 3❚.
Specification by Tissue Type
We found that the specification rate differed by tissue type ( Table 1 ). The specification rate of FNAC studies performed in pancreas was relatively high (47%), whereas the specification rate for salivary glands was relatively low (14%). The specification rates of other tissues were similar to the mean specification rate (33%).
Specification Rate by Item Type
We found that all of the items in our list of 17 specifications were reported in our sample of studies but with varying frequency. On average, items were specified 33% of the time (Table 3 ). The most frequently specified parameters were needle size (68%) and the type of routine ❚Figure 3❚ Distribution of parameters specified per study. The number of items specified per study is shown. In 5 studies, no parameters were specified, whereas 1 study specified 13 parameters. Studies most frequently specified 4 of the 17 items. logistic regression was used to assess the odds ratio (OR) for specification rate of each parameter, adjusting for the effect of period and journal type. Needle size was used as a reference (OR = 1). Multivariate logistic regression showed that, with the exception of staining method (Table  3 , parameter 8), the OR for the specification rate was significantly less than 1 (Table 3 ) ❚Figure 4❚. When grouped by category (Table 3 ; equation 2), our multivariate logistic model showed that sample collection had the highest specification rate (OR = 1.00), whereas sample preparation (OR = 0.60) and sample interpretation (OR = 0.55) had significantly lower specification rates. The specification rate of sample interpretation was not statistically different from that for sample preparation (χ 2 1 = 1.14, P ≤ .286).
Specification Rate by Publication Date
There was a trend toward increased reporting of specifications over time ❚Figure 5❚ and ❚Table 5❚. The overall specification rate was higher in 2000 and 2010 than in 1990. This seems to have been driven by an improvement in the specification rate of the parameters involved in sample collection. Multivariate logistic regression showed that the ORs for the specification rate were significantly higher in period 2 (z = 4.50; P < .001) and period 3 (z = 2.61; P < .009) relative to period 1. The specification rate in period 2 was not statistically different from period 3 (χ 2 1 = 3.55; P < .060).
Specification Rate by Journal Type
The specification rate by journal type is given in ❚Table 6❚ and ❚Figure 6❚. The data in Table 6 show that the average specification rates of studies published in pathology (37%), cytology (35%), and general medical journals (38%) are similar, but that the specification rate is lower in surgical journals (24%). Multivariate logistic regression showed that the ORs adjusted for other factors were significantly higher for studies appearing in pathology journals (z = 4.5; P < .000), cytology journals (z = 7.0; P < .000), and general medicine journals (z = 8.7; P < .000) relative to surgery journals ( Figure 6 ). There was no statistical difference in the specification rate of pathology and cytology journals (χ 2 1 = 0.02; P < .894) or cytology and general medicine journals (χ 2 1 = 1.71; P < .191); however, there was a statistically significant difference between pathology and general medicine journals (χ 2 1 = 3.55; P < .014).
Interrater Agreement
Interrater agreement statistics are given in ❚Table 7❚. 12 On average, evaluators showed 79% agreement; however, the observed levels of interrater agreement for specific items ranged from 69% (percentage of guided biopsies) to 94% (needle size). The overall average κ statistic was 0.42 and ranged from -0.05 (number of immunohistochemical stains) to 0.86 (needle size) for specific items. The agreement rate was correlated with the specification rate (ρ = 0.61; P = .01). On average, the rate of rate of agreement increased 1.6% for every percentage increase in specification rate ❚Figure 7❚. CT, computed tomography; US, ultrasound. * Frequency at which test parameters were specified (as percentages). The listing does not indicate that the parameter was present. Rather, it indicates that the parameter was specifically mentioned. For example, if a report mentioned that a cytologist was not present for immediate assessment, the report would be marked positive because it specified the parameter. A report would be marked negative if the parameter was not mentioned. CT, computed tomography; US, ultrasound. * Frequency at which test parameters were specified (as percentages). The listing does not indicate that the parameter was present. Rather, it indicates that the parameter was specifically mentioned. For example, if a report mentioned that a cytologist was not present for immediate assessment, the report would be marked positive because it specified the parameter. A report would be marked negative if the parameter was not mentioned.
specified (68%), but other items such as the experience level of the cytologist were infrequently specified (10%). The specification rate has improved somewhat since period 1, but the overall specification rate is quite low (34% in period 3). The low specification rate could indicate a general deficiency in the reporting of FNAC DTA studies or could be explained by other factors. For example, it is possible
Discussion
Our survey showed considerable variation in the specification rate for the list of 17 important test parameters that we identified. On average, studies specified 5 of 17 items, but individual studies ranged from a low of 0 to a high of 13 items. There was also considerable variation by parameter. Some parameters, such as needle size, were frequently ❚Figure 7❚ Relationship between percentage of agreement and specification rate. The best fit line and 95% confidence limits for the relationship between the specification rate and agreement rate are shown. The triangular point is an outlier and was omitted from the best fit calculation.
attempted to investigate factors that could explain the cause of the variability and, in particular, whether the variability in diagnostic accuracy could be explained by variation in FNAC technique. We found that methods were often poorly reported, and, as a consequence, it was impossible to do the statistical analysis. We decided to do this study to document the wide variability in reporting practice. Our study suggests that there is a need to improve how FNAC DTA studies are reported. More complete reporting would facilitate comparison of test results and help researchers identify the factors that affect test performance. Over time, such test comparisons could lead to general improvements in FNAC performance. It might be worthwhile to consider a checklist of specifications for diagnostic accuracy studies to facilitate more complete reporting. Such an approach (MIAME, minimum information about a microarray experiment 13 ) has been developed for microarray experiments that, like FNAC, are affected by many experimental factors. Not all FNAC studies would benefit from a method checklist; however, a set of common specifications would be useful in the context of DTA studies.
Our list of specifications should be regarded as preliminary. Our list of 17 specifications was obtained by examining the methods sections of DTA studies and is descriptive rather than prescriptive. Our list represents a set of parameters that cytologists frequently specify in FNAC DTA studies, but we have provided no objective evidence to show whether these items actually affect performance. The list of test parameters would require further verification and refinement before it could be adopted as a checklist. In addition, a checklist would require a common format for reporting, which our study has not addressed. Our intent is to raise awareness of the need for more complete reporting and standardization. We hope that this study will motivate cytopathologists to begin a discussion on the merits of a standardized reporting of test parameters in DTA studies. Over time, we would hope that the community of cytopathologists could reach consensus on a set of parameters that would facilitate comparisons between DTA studies and with other methods, such as core needle biopsy.
Our study is descriptive. The main objective was to document the degree to which method specification varies across studies. We have no opinion as to which of the 17 methodological criteria are most important; however, improvement can be made by only comparing studies in which these factors are described and compared. Our objective was not to determine whether there is a correlation between reporting and diagnostic accuracy. Rather, our objective was to suggest a path to determine which factors have an effect on accuracy. At present, the reporting of methods is so variable that it is generally impossible to make meaningful comparisons between studies. Our contention that studies would be improved by more complete reporting is based on that the overall specification rate was low because the items included in our survey are not generally regarded as important and, as a consequence, are not frequently specified. On the other hand, our poll of experienced cytopathologists rated all of the items as at least somewhat important. In addition, our study shows that each of the test parameters was specified with a frequency of at least 10% in the methods sections of DTA studies. While variable, the fact that each of the factors is sometimes specified in studies suggests that many study authors believe that these factors are important. While one would expect that some parameters would generally be regarded as more important than others, it would seem the threshold for reporting test parameters should be low in the context of a DTA study. We also would expect to see less variation if there were consensus that only a few of the items on our list were considered important.
The results might be attributed to features of the design or execution of our survey. We sampled a large number of studies and randomized the selection of studies, the order of evaluation, and the assignment of studies to evaluators. Each study was independently assessed by 3 evaluators. We found reasonable interrater agreement; however, there were several items in which the interrater agreement was low. Low agreement occurred primarily for parameters related to sample preparation. The observed agreement for these items was only slightly lower than items in the other categories, but the κ scores were significantly lower. The low rate of interrater agreement may have been due to differences of interpretation, failure to clearly specify the criteria for evaluation, or difficulties in assessment owing to poor reporting. The fact that the agreement increased with the specification rate suggests that it was easier for evaluators to assess specifications when they were affirmative compared with cases in which specification was lacking. The percentage of agreement is an alternative measure of agreement, and the confidence intervals for the percentage of agreement reflect the variation owing to interrater agreement. The confidence intervals for the 2 items with the lowest level of interrater agreement (use of special stains, specification rate: 19%, 95% confidence interval, 15%-24%; number of immunohistochemical stains used, specification rate: 13%, 95% confidence interval, 9%-17%) show that these numbers are reliable despite the low κ levels. Furthermore, the overall pattern of results (eg, low specification rate, variability in specification rate between items) is unchanged even if these 2 items are discounted. Overall, the measures of agreement were acceptable, and there is little reason to believe that our results are unrepresentative or invalid.
This study was motivated by a recent meta-analysis that we completed on the diagnostic accuracy of FNAC for parotid gland lesions. 11 In that study, we found considerable heterogeneity in diagnostic accuracy across study centers. We a long-term view of the research process. Over time, more complete reporting will facilitate the scientific process and enable us to determine which factors affect accuracy.
In the longer term, it is worth considering whether retrospective studies can provide sufficient detail to determine the factors that affect diagnostic accuracy. As we demonstrated in this study, there are many factors that potentially affect the accuracy of FNAC, and these often vary by case, eg, the use of immunohistochemical stains, cell blocks, the experience of the cytopathologist interpreting the case, the personnel who obtained the biopsy specimen. In a retrospective study, these specifications are usually reported as percentages (eg, 40% of the cases used ultrasound guidance) and the specifications are not linked to case outcomes. DTA studies would be much improved if results were reported at a case level and would facilitate individual-patient data meta-analysis. Individual-patient data meta-analysis is the "gold standard" for meta-analysis 14, 15 and has the potential to provide a greater understanding of the factors that affect the accuracy of FNAC than is possible by standard methods that report aggregate statistics. Standardized reporting of test conditions would be an important first step toward this goal.
FNAC requires many steps, and, for each step, there are a number of factors that can affect accuracy. It is important for all of the factors to be specified to make valid comparisons between DTA studies. We identified 17 test parameters that could affect the results of a diagnostic accuracy study. We found that most studies specified relatively few of these parameters, and, in addition, there was considerable variability in the reporting. There is a need for a more standardized approach for reporting test conditions in FNAC DTA studies.
